Pharma Deals Review, Vol 2003, No 33 (2003)

Font Size:  Small  Medium  Large

CAT and OGS in US$176 M Merger

Business Review Editor

Abstract


Cambridge Antibody Technology (CAT) and Oxford Glycosciences (OGS) entered into a merger agreement designed to create one of the strongest biotechnology companies in Europe. The deal could worth up to £109.6 M.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.